<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210208050295N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-03-03</date_registration>
      <primary_sponsor>Mashhad University of Medical Sciences</primary_sponsor>
      <public_title>The effect of Rosa damascena mill on menopausal symptoms</public_title>
      <acronym></acronym>
      <scientific_title>The effect of oral capsules Rosa damascena mill extract on menopausal symptoms</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-04-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>78</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54221</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Sampling will be done in all 8 comprehensive centers of health services in Gorgan. The researcher is present in each of these centers and based on the selecting the research unit checklist, women who are eligible to enter the study are selected as available method. The capsule containing Rosa damascena mill extract and placebo is provided to the researcher by the pharmacist consulting professor in similar forms with two different codes and only the pharmacist consulting professor is aware of the codes. Individuals eligible for the study will be randomly assigned to the drug or placebo group by random sequence, Blinding description: In order to blind the capsule of Rosa damascena mill extract and placebo in similar shapes and completely identical packages are provided to the researcher. Each of them has a code that only the pharmacist consultant knows. Eligible individual are randomly assigned to drug or placebo groups by random sequence. Therefore until the end of the study research units, researcher and statistician will not be aware of the codes related to drug and placebo groups.</study_design>
      <phase>3</phase>
      <hc_freetext>menopausal symptoms.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In this group, research units take a 500 mg capsule containing Rosa damascena mill hydro-alcoholic extract every 12 hours for 8 weeks. These capsules are prepared in the Department of Medicinal Plants Pharmacology of Mashhad University of Medical Sciences. According to the studies presented on Rosa damascena mill, 71 mg / kg per day of the alcoholic extract of this plant will not be toxic to humans. Intervention 2: Control group: In this group, research units take a placebo capsule every 12 hours for 8 weeks. Each of these capsules contains 500 mg of Avisel powder and is made with the appearance and packaging similar to Rosa damascena capsule in the Department of Medicinal Plants of Mashhad University of Medical Sciences.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is -</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Zohre Gholinezhad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing and Midwifery ,Doktota Crossroads, ,DaneshgahStreet,</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913199</zip>
        <telephone>+98 51 3859 1511</telephone>
        <email>Gholinezhadz982@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Fatemeh zahra Karimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Nursing and Midwifery,Doktora Crossroads, Daneshgah Street,</address>
        <city>Mashhad</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>9137913199</zip>
        <telephone>+98 51 3859 1511</telephone>
        <email>Karimifz@mums.ac.ir</email>
        <affiliation>Mashhad University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having a minimum education in primary school
Age 45 to 65 years old
Having a normal menopause (stopping menstruation for at least one year after 45 years old, without interfering with pregnancy and lactation, surgery, medication and pathology)
Married and living with her husband
Having sexual intercourse in the last month
Obtained at least 5 score from the initial MRS
Lack of known and treated medical diseases which affect the results of the study (cardiovascular, liver, kidney, chronic lung disorders, thyroid, neurology and psychiatry diseases, musculoskeletal, pelvic prolapse, urinary disorders and neurological diseases known and treated )
No history of cancer</inclusion_criteria>
      <agemin>45 years</agemin>
      <agemax>60 years</agemax>
      <gender>Female</gender>
      <exclusion_criteria>Drug addiction, smoking and alcohol abuse
Taken medicine that improve menopausal symptoms in the last 6 months (Such as estrogen and progesterone, GnRH agonists and antagonists, clonidine, gabapentin, serotonin and norepinephrine inhibitors, paroxetine, venlafaxine, vitamin E, methyldopa, naloxone and tibolone)
Use of complementary medicine to improve menopausal symptoms (such as herbs, acupuncture and acupressure) during the last 6 months
Women professional athletes or women with severe mobility limitations who are unable to do housework</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>GA30.00</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Any condition of the genital system affecting females, caused by pathological changes associated with the perimenopausal period, such as the permanent cessation of menstruation and infertility. Includes: Symptoms such as flushing, sleeplessness, headache,</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In this group, research units take a 500 mg capsule containing Rosa damascena mill hydro-alcoholic extract every 12 hours for 8 weeks. These capsules are prepared in the Department of Medicinal Plants Pharmacology of Mashhad University of Medical Sciences. According to the studies presented on Rosa damascena mill, 71 mg / kg per day of the alcoholic extract of this plant will not be toxic to humans.</i_keyword>
      <i_keyword>Control group: In this group, research units take a placebo capsule every 12 hours for 8 weeks. Each of these capsules contains 500 mg of Avisel powder and is made with the appearance and packaging similar to Rosa damascena capsule in the Department of Medicinal Plants of Mashhad University of Medical Sciences.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of menopause symptoms. Timepoint: At the beginning of the study (before the start of the study) and at the beginning of weeks 4 and 8 after the start of the study. Method of measurement: Menopause raring scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Depression, anxiety and stress in menopausal women. Timepoint: At the beginning of the study (before the start of the study) and at the beginning of weeks 4 and 8 after the start of the study. Method of measurement: Depression, Anxiety and Stress Scale.</sec_outcome>
      <sec_outcome>Quality of sleep in menopausal women. Timepoint: At the beginning of the study (before the start of the study) and at the beginning of weeks 4 and 8 after the start of the study. Method of measurement: Pittsburgh Sleep Quality Index.</sec_outcome>
      <sec_outcome>Sexual function in menopausal women. Timepoint: At the beginning of the study (before the start of the study) and at the beginning of weeks 4 and 8 after the start of the study. Method of measurement: Female sexual function index.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Mashhad University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-02-13</approval_date>
        <contact_name>School of Nursing and Midwifery, Mashhad University of Medical Sciences</contact_name>
        <contact_address>Faculty of Nursing and Midwifery, Doctora Crossroads, Daneshgah Street Mashhad Razavi Khorasan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
